162 related articles for article (PubMed ID: 37391511)
1. CRISPR prime editing for unconstrained correction of oncogenic KRAS variants.
Jang G; Kweon J; Kim Y
Commun Biol; 2023 Jun; 6(1):681. PubMed ID: 37391511
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells.
Lee W; Lee JH; Jun S; Lee JH; Bang D
Sci Rep; 2018 Aug; 8(1):11879. PubMed ID: 30089886
[TBL] [Abstract][Full Text] [Related]
3. Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
Sayed S; Sidorova OA; Hennig A; Augsburg M; Cortés Vesga CP; Abohawya M; Schmitt LT; Sürün D; Stange DE; Mircetic J; Buchholz F
Cancer Res; 2022 Sep; 82(17):3002-3015. PubMed ID: 35802645
[TBL] [Abstract][Full Text] [Related]
4. CRISPR and KRAS: a match yet to be made.
Bender G; Fahrioglu Yamaci R; Taneri B
J Biomed Sci; 2021 Nov; 28(1):77. PubMed ID: 34781949
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
6. CRISPR/Cas9-Mediated Knock-Out of Kras
Lentsch E; Li L; Pfeffer S; Ekici AB; Taher L; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739488
[TBL] [Abstract][Full Text] [Related]
7. A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing.
Jia S; Zhang R; Lin G; Peng R; Gao P; Han Y; Fu Y; Ding J; Wu Q; Zhang K; Xie J; Li J
J Clin Lab Anal; 2018 Jun; 32(5):e22391. PubMed ID: 29380513
[TBL] [Abstract][Full Text] [Related]
8. A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.
Budagyan K; Chernoff J
Methods Mol Biol; 2021; 2262():323-334. PubMed ID: 33977487
[TBL] [Abstract][Full Text] [Related]
9. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
10. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
Tong JH; Lung RW; Sin FM; Law PP; Kang W; Chan AW; Ma BB; Mak TW; Ng SS; To KF
Cancer Biol Ther; 2014 Jun; 15(6):768-76. PubMed ID: 24642870
[TBL] [Abstract][Full Text] [Related]
11. A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.
Budagyan K; Cannon AC; Chernoff J
Methods Mol Biol; 2024; 2797():351-362. PubMed ID: 38570472
[TBL] [Abstract][Full Text] [Related]
12. Prime Editing: An Emerging Tool in Cancer Treatment.
Sen D; Sarkar S; Mukhopadhyay P
Mol Biotechnol; 2023 Apr; 65(4):509-520. PubMed ID: 36251123
[TBL] [Abstract][Full Text] [Related]
13. Detection of
Michaelidou K; Koutoulaki C; Mavridis K; Vorrias E; Papadaki MA; Koutsopoulos AV; Mavroudis D; Agelaki S
Cells; 2020 Nov; 9(11):. PubMed ID: 33233668
[No Abstract] [Full Text] [Related]
14. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
15. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
16. Novel activating KRAS mutation candidates in lung adenocarcinoma.
Abe J; Tanuma N; Nomura M; Ito S; Kasugai I; Sato I; Tamai K; Mochizuki M; Yamaguchi K; Shima H; Okada Y; Yasuda J
Biochem Biophys Res Commun; 2020 Feb; 522(3):690-696. PubMed ID: 31787238
[TBL] [Abstract][Full Text] [Related]
17. Sensitive Detection of KRAS Mutations by Clustered Regularly Interspaced Short Palindromic Repeats.
Zhou H; Tsou JH; Leng Q; Jiang F
Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33467412
[TBL] [Abstract][Full Text] [Related]
18. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
[TBL] [Abstract][Full Text] [Related]
19. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
[TBL] [Abstract][Full Text] [Related]
20. A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.
Sinha S; Barbosa K; Cheng K; Leiserson MDM; Jain P; Deshpande A; Wilson DM; Ryan BM; Luo J; Ronai ZA; Lee JS; Deshpande AJ; Ruppin E
Nat Commun; 2021 Nov; 12(1):6512. PubMed ID: 34764240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
